16.68
Precedente Chiudi:
$16.51
Aprire:
$16.43
Volume 24 ore:
297.23K
Relative Volume:
0.88
Capitalizzazione di mercato:
$428.51M
Reddito:
-
Utile/perdita netta:
$11.77M
Rapporto P/E:
28.83
EPS:
0.5785
Flusso di cassa netto:
$-19.23M
1 W Prestazione:
+8.88%
1M Prestazione:
+2.61%
6M Prestazione:
-35.94%
1 anno Prestazione:
+23.37%
Tourmaline Bio Inc Stock (TRML) Company Profile
Nome
Tourmaline Bio Inc
Settore
Industria
Telefono
646-481-9832
Indirizzo
27 WEST 24TH STREET, NEW YORK
Confronta TRML con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
TRML
Tourmaline Bio Inc
|
16.68 | 393.55M | 0 | 11.77M | -19.23M | 0.5785 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-23 | Iniziato | Chardan Capital Markets | Buy |
2025-03-06 | Iniziato | Wedbush | Outperform |
2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
2024-11-11 | Reiterato | H.C. Wainwright | Buy |
2023-12-15 | Iniziato | Jefferies | Buy |
2023-12-04 | Ripresa | H.C. Wainwright | Buy |
2023-11-17 | Iniziato | Truist | Buy |
2023-10-31 | Iniziato | Guggenheim | Buy |
2023-10-25 | Iniziato | Piper Sandler | Overweight |
2022-10-20 | Iniziato | H.C. Wainwright | Buy |
2022-07-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mostra tutto
Tourmaline Bio Inc Borsa (TRML) Ultime notizie
Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey
H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India
Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World
Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com
Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World
BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia
Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria
BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria
Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com
Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter
In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com
Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus
Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha
Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga
Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive
Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks
Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News
Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com
Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com
Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks
Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq
Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha
Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com
Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia
Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus
Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire
Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan
Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com India
Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times
Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq
Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan
Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World
Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks
Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World
Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World
Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World
Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World
Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World
Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World
FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World
Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World
FY2025 EPS Estimates for Tourmaline Bio Raised by Analyst - Defense World
Tourmaline Bio Q2 EPS Estimate Decreased by HC Wainwright - Defense World
Analysts Set Expectations for Tourmaline Bio Q2 Earnings - Defense World
HC Wainwright Predicts Tourmaline Bio Q2 Earnings - Defense World
Tourmaline Bio Inc Azioni (TRML) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):